Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies

Jessica F. Olive; Yuanbo Qin; Molly J. DeCristo; Tyler Laszewski; Frances Greathouse; Sandra S. McAllister

doi:10.1371/journal.pone.0198790

Loading metrics

Open Access

Peer-reviewed

Research Article

Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies

Jessica F. Olive ,

Contributed equally to this work with: Jessica F. Olive, Yuanbo Qin

Roles Data curation, Formal analysis, Writing – original draft, Writing – review & editing

Affiliations Department of Medicine, Division of Hematology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
⨯
Yuanbo Qin ,

Contributed equally to this work with: Jessica F. Olive, Yuanbo Qin

Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – review & editing

Affiliations Department of Medicine, Division of Hematology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
⨯
Molly J. DeCristo,

Roles Data curation, Formal analysis

Affiliations Department of Medicine, Division of Hematology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
⨯
Tyler Laszewski,

Roles Data curation

Affiliation Department of Medicine, Division of Hematology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
⨯
Frances Greathouse,

Roles Data curation

Affiliation Department of Medicine, Division of Hematology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
⨯
Sandra S. McAllister

Roles Conceptualization, Funding acquisition, Supervision, Writing – review & editing

* E-mail: smcallister1@bwh.harvard.edu

Affiliations Department of Medicine, Division of Hematology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America, Harvard Stem Cell Institute, Cambridge, Massachusetts, United States of America

http://orcid.org/0000-0002-5111-5903

⨯

Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies

Jessica F. Olive,
Yuanbo Qin,
Molly J. DeCristo,
Tyler Laszewski,
Frances Greathouse,
Sandra S. McAllister

Published: June 13, 2018
https://doi.org/10.1371/journal.pone.0198790

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.
Cloning
Is the Subject Area "Cloning" applicable to this article?

Thanks for your feedback.
Lung and intrathoracic tumors
Is the Subject Area "Lung and intrathoracic tumors" applicable to this article?

Thanks for your feedback.
Cancer epidemiology
Is the Subject Area "Cancer epidemiology" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.